OBD was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of diagnostic products for cancer and other diseases. The parental patent covering EpiSwitch™ technology was filed in February 2007, and today it has already been granted in South Africa, Singapore, New Zealand and Europe.
The Company started its operations from its first reference laboratory in the University Science Park at Begbroke, Oxford. Today, Company Offices, Reference Laboratory, Quality Control and Quality Assurance facilities are centralised at 26 Beaumont Street, Oxford, in the very centre of the historical University city.
Oxford BioDynamics’ leadership team has extensive biotechnology, health and commercial experience and as such works as a dynamic unit committed to researching epigenetics and producing reliable methods of screening, diagnosis and monitoring of diseases with aberrant gene expression.
